125 related articles for article (PubMed ID: 16830054)
1. Role of circulating cytokeratin fragments and angiogenic factors in NSCLC patients stage IIIa-IIIb receiving curatively intended treatment.
Eriksson P; Brattström D; Hesselius P; Larsson A; Bergström S; Ekman S; Goike H; Wagenius G; Brodin O; Bergqvist M
Neoplasma; 2006; 53(4):285-90. PubMed ID: 16830054
[TBL] [Abstract][Full Text] [Related]
2. Basic fibroblast growth factor and vascular endothelial growth factor in sera from non-small cell lung cancer patients.
Brattström D; Bergqvist M; Larsson A; Holmertz J; Hesselius P; Rosenberg L; Brodin O; Wagenius G
Anticancer Res; 1998; 18(2A):1123-7. PubMed ID: 9615776
[TBL] [Abstract][Full Text] [Related]
3. Basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) levels, as prognostic indicators in NSCLC.
Iwasaki A; Kuwahara M; Yoshinaga Y; Shirakusa T
Eur J Cardiothorac Surg; 2004 Mar; 25(3):443-8. PubMed ID: 15019676
[TBL] [Abstract][Full Text] [Related]
4. Angiogenesis in non-small cell lung cancer: the prognostic impact of neoangiogenesis and the cytokines VEGF and bFGF in tumours and blood.
Bremnes RM; Camps C; Sirera R
Lung Cancer; 2006 Feb; 51(2):143-58. PubMed ID: 16360975
[TBL] [Abstract][Full Text] [Related]
5. Circulating angiogenic cytokines in multiple myeloma and related disorders.
Urba ska-Rys H; Wierzbowska A; Robak T
Eur Cytokine Netw; 2003; 14(1):40-51. PubMed ID: 12799213
[TBL] [Abstract][Full Text] [Related]
6. [Plasma level and prognostic significance of VEGF, bFGF and MMP-9 in patients with advanced non-small-cell lung cancer].
Zhao J; Liu XY; Zhang QY; Jiang W
Zhonghua Zhong Liu Za Zhi; 2005 Nov; 27(11):676-9. PubMed ID: 16438890
[TBL] [Abstract][Full Text] [Related]
7. Serum vascular endothelial growth factor (VEGF) and bcl-2 levels in advanced stage non-small cell lung cancer.
Tas F; Duranyildiz D; Oguz H; Camlica H; Yasasever V; Topuz E
Cancer Invest; 2006 Oct; 24(6):576-80. PubMed ID: 16982461
[TBL] [Abstract][Full Text] [Related]
8. The role of MonoTotal in the primary diagnosis, prognosis and follow-up of patients with non-small cell lung cancer (NSCLC).
Prazakova M; Vrzalova J; Auge JM; Safranek J; Topolcan O; Fuchsova R; Spisakova M; Svobodova S; Holubec L; Pesta M
Anticancer Res; 2011 Sep; 31(9):3107-12. PubMed ID: 21868567
[TBL] [Abstract][Full Text] [Related]
9. The combination assay with circulating vascular endothelial growth factor (VEGF)-C, matrix metalloproteinase-9, and VEGF for diagnosing lymph node metastasis in patients with non-small cell lung cancer.
Tamura M; Oda M; Matsumoto I; Tsunezuka Y; Kawakami K; Ohta Y; Watanabe G
Ann Surg Oncol; 2004 Oct; 11(10):928-33. PubMed ID: 15383417
[TBL] [Abstract][Full Text] [Related]
10. [Basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) are elevated in peripheral blood plasma of patients with chronic lymphocytic leukemia and decrease after intensive fludarabine-based treatment].
Smolej L; Andrýs C; Krejsek J; Belada DZ; Zák P; Siroký O; Malý J
Vnitr Lek; 2007 Nov; 53(11):1171-6. PubMed ID: 18277626
[TBL] [Abstract][Full Text] [Related]
11. Early increase in serum levels of the angiogenesis-inhibitor endostatin and of basic fibroblast growth factor in melanoma patients during disease progression.
Kurschat P; Eming S; Nashan D; Krieg T; Mauch C
Br J Dermatol; 2007 Apr; 156(4):653-8. PubMed ID: 17263813
[TBL] [Abstract][Full Text] [Related]
12. Angiogenetic biomarkers in non-small cell lung cancer with malignant pleural effusion: correlations with patient survival and pleural effusion control.
Hsu IL; Su WC; Yan JJ; Chang JM; Lai WW
Lung Cancer; 2009 Sep; 65(3):371-6. PubMed ID: 19157636
[TBL] [Abstract][Full Text] [Related]
13. Vascular endothelial growth factor immunostaining correlates with postoperative relapse and survival in non-small cell lung cancer.
Yilmaz A; Ernam D; Unsal E; Demirag F; Atikcan S; Taştepe I
Arch Med Res; 2007 Oct; 38(7):764-8. PubMed ID: 17845896
[TBL] [Abstract][Full Text] [Related]
14. [Vascular endothelial growth factor promotes hematogenous metastasis of cancer cells in patients with non-small cell lung cancer].
Dong Q; Feng J; Huang J; Bao G; Sha H; Gu W
Zhonghua Zhong Liu Za Zhi; 2002 Mar; 24(2):142-6. PubMed ID: 12015035
[TBL] [Abstract][Full Text] [Related]
15. High pretreatment serum concentration of basic fibroblast growth factor is a predictor of poor prognosis in small cell lung cancer.
Ruotsalainen T; Joensuu H; Mattson K; Salven P
Cancer Epidemiol Biomarkers Prev; 2002 Nov; 11(11):1492-5. PubMed ID: 12433733
[TBL] [Abstract][Full Text] [Related]
16. Comparison of serum growth factors and tumor markers as prognostic factors for survival in non-small cell lung cancer.
Nieder C; Andratschke N; Jeremic B; Molls M
Anticancer Res; 2003; 23(6D):5117-23. PubMed ID: 14981976
[TBL] [Abstract][Full Text] [Related]
17. Soluble syndecan-1 and serum basic fibroblast growth factor are new prognostic factors in lung cancer.
Joensuu H; Anttonen A; Eriksson M; Mäkitaro R; Alfthan H; Kinnula V; Leppä S
Cancer Res; 2002 Sep; 62(18):5210-7. PubMed ID: 12234986
[TBL] [Abstract][Full Text] [Related]
18. [The estimation of serum concentration of vascular endothelial growth factor in patients with non-small cell lung cancer].
Kopczyńska E; Dancewicz M; Kowalewski J; Kardymowicz H; Tyrakowski T
Pol Merkur Lekarski; 2007 Jun; 22(132):536-8. PubMed ID: 17874624
[TBL] [Abstract][Full Text] [Related]
19. Tissue polypeptide specific antigen (tps) and cytokeratin 19 fragment (CYFRA 21.1) immunoradiometric assay in non small cell lung cancer evaluation.
Giovanella L; Ceriani L; Bandera M; Rimoldi R; Beghé B; Roncari G
Q J Nucl Med; 1995 Dec; 39(4):285-9. PubMed ID: 8624791
[TBL] [Abstract][Full Text] [Related]
20. Circulating angiogenic growth factor levels in mice bearing human tumors using Luminex Multiplex technology.
Keyes KA; Mann L; Cox K; Treadway P; Iversen P; Chen YF; Teicher BA
Cancer Chemother Pharmacol; 2003 Apr; 51(4):321-7. PubMed ID: 12721760
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
